The Future of Bladder Cancer
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.
Clinical Pearls:
- Within the next 10 years, physicians will have hopefully moved away from using chemotherapy to treat patients with bladder cancer
- Physicians need to refine their understanding of the genetic makeup of bladder cancer in order identify validating predictive biomarkers
- Hopefully in the future, physicians will be able to biopsy a tumor in real time, identify actionable alterations in the patient’s tumor, and select a particular therapy based on the findings
Recent Videos
Related Content
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
October 28th 2024Article
TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
Read More
